Cytyc Corporation Receives 2006 Insight Award for Excellence in Healthcare Communications; Aboutheavyperiods.com Recognized as an Outstanding Resource for Women.

MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC), a leading provider of surgical and diagnostic products targeting cancer diagnostics and women's health, today announced that it received the 2006 Insight Award for Customer Advocacy in Healthcare Communications for its new website, http://aboutheavyperiods.com. Cytyc was selected among 47 nominees to receive the award for providing valuable information to consumers, enabling informed healthcare choices. The award was presented earlier this week at the 2nd Annual Healthcare Communications Forum in Boston, Massachusetts.

Cytyc was recognized for creating http://aboutheavyperiods.com, an online resource that clearly explains the signs, symptoms, and available treatment options for menorrhagia, or excessive menstrual bleeding; a condition that afflicts approximately seven million women in the United States. Cytyc enlisted an advisory board of physicians to review and edit the website's content to ensure accuracy. The site also includes a patient self-assessment quiz and a link to find a local physician who has special interest in treating heavy periods.

"Aboutheavyperiods.com is filled with educational content communicated in plain language that makes it easy for consumers to learn about the condition and treatment options," said Professor Deborah Bosley, director of the Center for Writing, Language, and Literacy at the University of North Carolina - Charlotte and one of three judges for the 2006 Insight Award for Customer Advocacy in Healthcare Communications. "I'd like to see more of these easy-to-understand health communication materials throughout the healthcare industry because they create increased awareness and understanding among consumers about important healthcare issues."

"Cytyc is dedicated to educating women about menorrhagia and empowering them with the knowledge to seek treatment for this debilitating condition," said Ellen Sheets, M.D., senior vice president and chief medical officer at Cytyc Corporation and Advisory Board Member of http://aboutheavyperiods.com. "We thank Art Plus Technology for recognizing our work to educate women about menorrhagia and look forward to updating the site with additional resources that will continue to help women make informed decisions about their health."

About Cytyc Corporation

Cytyc Corporation is a leading provider of best-in-class medical technology that enables physicians and laboratories to improve patient's lives throughout the world. Cytyc provides diagnostic and minimally invasive surgical products targeting cancer and women's health. The ThinPrep(R) System is the most widely used method for cervical cancer screening in the United States. The ThinPrep System consists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor, ThinPrep(R) Imaging System, and related reagents, filters, and other supplies. The ThinPrep System also provides the platform from which the Company launched its expansion into breast cancer risk assessment with the FirstCyte(R) Breast Test. The MammoSite(R) Radiation Therapy System is a single-use device for the treatment of breast cancer that positions radiation sources directly into the post-lumpectomy site to optimize radiation treatment delivery while minimizing damage to healthy tissue. The NovaSure(R) Impedance Controlled Endometrial Ablation System, or the NovaSure(R) System, is an innovative endometrial ablation device to treat menorrhagia, or excessive menstrual bleeding.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. Cytyc, ThinPrep, FirstCyte, NovaSure, and MammoSite are registered trademarks of Cytyc Corporation.

About Art Plus Technology

Art Plus Technology is a Boston-based firm that specializes in designing and implementing complex financial and healthcare transactional communications. APT helps clients develop more lasting, profitable, and cost-effective relationships with their customers and intermediaries. APT achieves simplicity by managing complexity. Visit www.artplustechnology.com

Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding key customer relationships, future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and customers as well as reliance on proprietary technology, uncertainty of product development efforts and product acceptance, management of growth, product diversification, and organizational change, entry into new market segments domestically and new markets internationally, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies in the United States and abroad, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in its 2005 Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.